Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Abstract

The profile of action in animals of CQP 201-403, a novel 8 alpha-amino-ergoline, is in most aspects that of a very potent dopaminomimetic, both as a prolactin secretion inhibitor, and at the levels of the CNS and the cardiovascular system. Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). In man the new compound proved to be highly active in lowering prolactin serum levels and be more potent than bromocriptine (Parlodel).

• Authors: E Flückiger, U Briner, B Clark, A Closse, A Enz, P Gull, A Hofmann, R Markstein, L Tolcsvai, H R Wagner
• Journal: Experientia (Experientia) Vol. 44 Issue 5 Pg. 431-6 (May 15 1988) ISSN: 0014-4754 [Print] Switzerland
• PMID: 3371446 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Ergolines
• CQP 201-403
• Serotonin
• Prolactin
• Dopamine
• Norepinephrine

Topics

• Animals
• Behavior, Animal (drug effects)
• Binding, Competitive
• Brain (metabolism)
• Cell Membrane (metabolism)
• Dogs
• Dopamine (metabolism)
• Embryo Implantation (drug effects)
• Ergolines (metabolism, pharmacology)
• Female
• Hemodynamics (drug effects)
• Lactation (drug effects)
• Male
• Mice
• Milk Ejection (drug effects)
• Motor Activity (drug effects)
• Norepinephrine (metabolism)
• Pregnancy
• Prolactin (blood)
• Rats
• Rats, Inbred Strains
• Serotonin (metabolism)